Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
Purple Biotech Ltd., a foreign private issuer based in Rehovot, Israel, filed this Form 6-K on September 5, 2025, covering the month of September 2025. The filing primarily serves to disclose the pricing of a public offering and incorporates various exhibits related to the transaction.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on the announcement of a capital raise rather than reporting operational financial results for the period.
Material Changes and Transactions
- Public Offering: The company announced the pricing of a public offering of up to $18 million.
- Securities Issued: The offering includes Pre-Funded Warrants, Warrants, and Placement Agent Warrants, as detailed in the attached exhibits.
- Agreements: A Securities Purchase Agreement was executed to facilitate the transaction.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the standard legal disclaimer. The document explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the final closing amount of the $18 million public offering.
- Review the specific terms of the Pre-Funded Warrants and Placement Agent Warrants in the attached exhibits.
- Confirm the use of proceeds from the offering as disclosed in the full Press Release (Exhibit 99.1).
- Check for any subsequent filings regarding the completion of the offering.